Overactive Bladder | Treatment Algorithms | Claims Data Analysis | US | 2018

MARKET OUTLOOK

The well-established antimuscarinic drug class dominates the overactive bladder (OAB) therapy market, and the continued generic erosion of these agents will be the most significant constraint on the market’s future growth. However, for patients in whom these drugs are not effective, the options are limited. The two most recent market entrants, Astellas’s Myrbetriq and Allergan’s Botox (both of which offer alternative MOAs), have enjoyed strong growth in this market driven by a need for therapies effective in patients who are refractory to the antimuscarinics, by direct-to-consumer promotion, and by life-cycle management strategies used by their developers.

QUESTIONS ANSWERED

• What patient share do key therapies and brands garner by line of therapy in newly diagnosed OAB patients? What are the quarterly trends in prescribing among recently treated and new diagnosed OAB patients?
• How have more-recent market entrants such as Myrbetriq and Botox been integrated into the OAB treatment algorithm?
• What proportion of OAB patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of OAB patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
• What are the product-level compliance and persistency rates among drug-treated patients with OAB?

PRODUCT DESCRIPTION:

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.

Geographies: United States

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Botox, Myrbetriq, oxybutynin, Vesicare

Key analysis provided:

• Brand use across longitudinal patient sample.
• Newly diagnosed patient analysis.
• Treatment initiation and progression.
• Line of therapy analysis.
• Combination therapy analysis.
• Source of business for recently treated patients.
• Persistency and compliance analysis.
• Product-level patient flowcharts.